Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast
The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. In the last 30 years, only two immunotherapies have been approved in this indication: Genentech’s Tecentriq in 2019 and AstraZeneca’s Imfinzi in 2020 for treatment of extensive-stage disease across the G7 markets. Despite approval of these drugs, a substantial unmet need remains for better therapeutic options, especially in the later lines of therapy. However, the modest late-phase pipeline for SCLC is set to boost the market—namely, with Amgen’s bispecific T-cell engager (BiTE) tarlatamab and Daiichi’s antibody-drug conjugate (ADC) ifinatamab deruxtecan. Nevertheless, considerable commercial potential remains for targeted agents that treat the underserved relapsed/refractory SCLC population.
Questions Answered
- What are interviewed experts’ insights on the current treatment options for SCLC?
- How large are the drug-treatable SCLC populations, and how will drug-treatment rates change over time?
- How will key emerging therapies shape the SCLC market over the 10-year forecast period?
- What key factors are driving or constraining market growth?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Market share of drug classes for small-cell lung cancer: 2022
- Market share of drug classes for small-cell lung cancer: 2032
- Drug-treatable population share and major-market sales share in small-cell lung cancer: 2022
- Drug-treatable population share and major-market sales share in small-cell lung cancer: 2032
- Population positioning of therapies in small-cell lung cancer
- Small-cell lung cancer SWOT analysis
- Market drivers and constraints
- Segment-specific trends
- Key findings
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
Sudha Malhotra, M.S., Ph.D., is an analyst on the Oncology team at Clarivate. She is responsible for performing secondary market analysis, including patent research, pricing, and clinical trial assessment in the major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology in New Delhi, India, and has authored several peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences, both from the University of Delhi.
Atul Sharma, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. He holds a master’s degree in public health from the School of Public Health, Post-Graduate Institute of Medical Education and Research, and a bachelor’s degree in dental surgery from MN DAV Dental College and Hospital.
Sorcha Cassidy, M.Res., Ph.D., is an associate director on the Oncology team at Clarivate. She manages a team of analysts who produce syndicated primary and secondary market research reports and custom analysis on a wide range of oncology indications. Dr. Cassidy also provides client support for all oncology products and has expertise in hematologic malignancies and CAR T-cell therapies. She has published oncology market assessment articles in Nature Reviews Drug Discovery. Previously, Dr. Cassidy was a market research manager at Janssen UK. She obtained her M.Res. and Ph.D. in immunology from Imperial College London, where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIRs]) on natural killer cells in various diseases.